Literature DB >> 29987339

[Role of stereotactic body radiation therapy for unresected pancreatic cancer].

Jana Heitmann1, Matthias Guckenberger2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29987339     DOI： 10.1007/s00066-018-1331-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

Review 1.  SBRT in pancreatic cancer: what is the therapeutic window?

Authors:  Thomas B Brunner; Ursula Nestle; Anca-Ligia Grosu; Mike Partridge
Journal:  Radiother Oncol       Date:  2014-11-25       Impact factor: 6.280

2.  Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.

Authors:  Karyn A Goodman; Ellen A Wiegner; Katherine E Maturen; Zhigang Zhang; Qianxing Mo; George Yang; Iris C Gibbs; George A Fisher; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-28       Impact factor: 7.038

3.  A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer.

Authors:  James D Murphy; Claudia Christman-Skieller; Jeff Kim; Sonja Dieterich; Daniel T Chang; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-14       Impact factor: 7.038

4.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

Authors:  Patrick J Loehrer; Yang Feng; Higinia Cardenes; Lynne Wagner; Joanna M Brell; David Cella; Patrick Flynn; Ramesh K Ramanathan; Christopher H Crane; Steven R Alberts; Al B Benson
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Phase II study on stereotactic body radiotherapy of colorectal metastases.

Authors:  Morten Hoyer; Henrik Roed; Anders Traberg Hansen; Lars Ohlhuis; Jorgen Petersen; Hanne Nellemann; Anne Kiil Berthelsen; Cai Grau; Svend Aage Engelholm; Hans Von der Maase
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

6.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Authors:  Pascal Hammel; Florence Huguet; Jean-Luc van Laethem; David Goldstein; Bengt Glimelius; Pascal Artru; Ivan Borbath; Olivier Bouché; Jenny Shannon; Thierry André; Laurent Mineur; Benoist Chibaudel; Franck Bonnetain; Christophe Louvet
Journal:  JAMA       Date:  2016-05-03       Impact factor: 56.272

7.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

Authors:  B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

8.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860
  8 in total
  1 in total

1.  Shear Wave Elastography Can Differentiate between Radiation-Responsive and Non-responsive Pancreatic Tumors: An ex Vivo Study with Murine Models.

Authors:  Hexuan Wang; Bradley Mills; Reem Mislati; Rifat Ahmed; Scott A Gerber; David Linehan; Marvin M Doyley
Journal:  Ultrasound Med Biol       Date:  2019-11-11       Impact factor: 2.998
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.